SCHEMBL4245941

SCHEMBL4245941

Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3)n[nH]c2N[C@H](C)CO)ccc1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK11 Q15759 6/20 0.54
MAPK13 O15264 5/20 0.54
CYP2C9 P11712 1/20 0.54
MAPK14 Q16539 6/20 0.40
MAPK12 P53778 4/20 0.40
FGFR1 P11362 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
AHR P35869 1/20 0.33
ADORA1 P30542 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
P2RX3 P56373 1/20 0.32
P2RX2 Q9UBL9 1/20 0.32
KCNH3 Q9ULD8 2/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
PRKD1 Q15139 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4246294 0.86 MAPK11 (0.55) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4760876 0.85 MAPK13 (0.51) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL5812295 0.85 MAPK13 (0.53) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4760396 0.85 MAPK11 (0.48) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4760399 0.85 MAPK11 (0.48) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4760390 0.85 MAPK11 (0.48) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL5811657 0.84 MAPK11 (0.54) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4243526 0.84 MAPK13 (0.48) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4245986 0.83 MAPK13 (0.53) MAPK11MAPK13CYP2C9MAPK14MAPK12
SCHEMBL4246031 0.83 MAPK13 (0.49) MAPK11MAPK13CYP2C9MAPK14MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN ASTELLAS PHARMA INC (JP) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042856-A1 PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN HRH2, OPRD1, HRH4 MAPK11 1195/4885MAPK13 1439/4885CYP2C9 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.